PainReform Ltd. (PRFX) 10-Year Financial Performance & Capital Metrics

PRFX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

AboutPainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.Show more

Revenue $0
EBITDA -$15M -53.2%
Net Income -$15M -56.1%
EPS (Diluted) -32.16 +81.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -321.92% -214.6%
ROIC -
Debt/Equity 0.02 +107.7%
Interest Coverage -1048.07 -4099.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM76.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.84%

ROCE

10Y Avg-336.49%

5Y Avg-107.45%

3Y Avg-155.87%

Latest-305.59%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	86K	0	0
Revenue Growth %	-	-	-	-	-	-	-1%	-
Cost of Goods Sold+	0	0	1K	0	7K	15K	15K	16K
COGS % of Revenue	-	-	-	-	-	0.17%	-	-
Gross Profit+	0	0	-1K	0	-7K	71K	-15K	-16K
Gross Margin %	-	-	-	-	-	0.83%	-	-
Gross Profit Growth %	-	-	-	1%	-	11.14%	-1.21%	-0.07%
Operating Expenses+	877K	500K	689K	1.67M	7.21M	8.87M	9.58M	14.66M
OpEx % of Revenue	-	-	-	-	-	103.13%	-	-
Selling, General & Admin	376K	277K	553K	1.32M	4.35M	4.45M	3.55M	2.95M
SG&A % of Revenue	-	-	-	-	-	51.71%	-	-
Research & Development	504K	223K	136K	354K	2.86M	4.42M	6.04M	11.71M
R&D % of Revenue	-	-	-	-	-	51.42%	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-880K	-500K	-689K	-1.67M	-7.21M	-8.87M	-9.58M	-14.67M
Operating Margin %	-	-	-	-	-	-103.13%	-	-
Operating Income Growth %	-	0.43%	-0.38%	-1.43%	-3.31%	-0.23%	-0.08%	-0.53%
EBITDA+	0	0	-688K	-1.67M	-7.2M	-8.85M	-9.57M	-14.66M
EBITDA Margin %	-	-	-	-	-	-102.95%	-	-
EBITDA Growth %	-	-	-	-1.43%	-3.31%	-0.23%	-0.08%	-0.53%
D&A (Non-Cash Add-back)	880K	500K	1K	1K	7K	15K	15K	16K
EBIT	-880K	-503K	-689K	-1.67M	-7.23M	-8.77M	-9.58M	-14.57M
Net Interest Income+	0	0	-540.41K	-985.95K	-10K	99K	22K	87K
Interest Income	245K	0	588	1.05K	0	160K	406K	101K
Interest Expense	0	324K	541K	987K	10K	61K	384K	14K
Other Income/Expense	-242K	-328K	-590K	-2.16M	-32K	86K	248K	93K
Pretax Income+	-1.12M	-828K	-1.28M	-3.83M	-7.24M	-8.78M	-9.34M	-14.58M
Pretax Margin %	-	-	-	-	-	-102.13%	-	-
Income Tax+	0	4K	0	220K	6K	9K	8K	8K
Effective Tax Rate %	1.86%	1%	1.42%	1.06%	1%	1%	1%	1%
Net Income+	-2.09M	-828K	-1.82M	-4.05M	-7.25M	-8.79M	-9.34M	-14.59M
Net Margin %	-	-	-	-	-	-102.23%	-	-
Net Income Growth %	-	0.6%	-1.2%	-1.23%	-0.79%	-0.21%	-0.06%	-0.56%
Net Income (Continuing)	-1.12M	-828K	-1.28M	-4.05M	-7.25M	-8.79M	-9.34M	-14.59M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-36.25	-48.32	-62.11	-83.05	-177.23	-197.92	-171.33	-32.16
EPS Growth %	-	-0.33%	-0.29%	-0.34%	-1.13%	-0.12%	0.13%	0.81%
EPS (Basic)	-36.67	-14.53	-62.11	-83.05	-177.23	-197.92	-171.33	-32.16
Diluted Shares Outstanding	57.66K	57.66K	38.78K	48.8K	40.88K	44.42K	54.54K	453.54K
Basic Shares Outstanding	57K	57K	38.78K	48.8K	40.88K	44.42K	54.54K	453.54K
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	213K	80K	972K	17.79M	19.02M	12.28M	9.8M	4.43M
Cash & Short-Term Investments	187K	40K	941K	15.68M	16.54M	4.1M	8.03M	4.26M
Cash Only	187K	40K	941K	15.68M	16.54M	4.1M	8.03M	4.26M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	28K	22K	53K	218K	55K	45K	119K
Days Sales Outstanding	-	-	-	-	-	233.43	-	-
Inventory	0	0	0	2.04M	0	7.82M	0	0
Days Inventory Outstanding	-	-	-	-	-	190.36K	-	-
Other Current Assets	26K	6K	6K	33K	507K	0	10K	10K
Total Non-Current Assets+	1K	1K	192K	10K	53K	44K	131K	97K
Property, Plant & Equipment	1K	1K	0	10K	53K	44K	131K	97K
Fixed Asset Turnover	-	-	-	-	-	1.95x	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	192K	0	0	0	0	0
Total Assets+	214K	81K	1.16M	17.8M	19.07M	12.33M	9.93M	4.53M
Asset Turnover	-	-	-	-	-	0.01x	-	-
Asset Growth %	-	-0.62%	13.37%	14.29%	0.07%	-0.35%	-0.19%	-0.54%
Total Current Liabilities+	135K	18K	6.34M	961K	757K	1.06M	2.41M	2.44M
Accounts Payable	64K	2K	0	720K	136K	209K	221K	296K
Days Payables Outstanding	-	-	-	-	7.09K	5.09K	5.38K	6.75K
Short-Term Debt	0	0	6.17M	0	0	0	0	45K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	71K	16K	-166K	0	0	0	465K	152K
Current Ratio	1.58x	4.44x	0.15x	18.51x	25.13x	11.55x	4.07x	1.81x
Quick Ratio	1.58x	4.44x	0.15x	16.39x	25.13x	4.19x	4.07x	1.81x
Cash Conversion Cycle	-	-	-	-	-	185.51K	-	-
Total Non-Current Liabilities+	3.71M	4.52M	447K	220K	234K	243K	281K	259K
Long-Term Debt	3.71M	4.52M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	30K	0
Deferred Tax Liabilities	0	0	0	220K	234K	243K	251K	0
Other Non-Current Liabilities	0	0	447K	220K	0	0	0	259K
Total Liabilities	3.84M	4.54M	6.79M	1.18M	991K	1.31M	2.69M	2.7M
Total Debt+	3.71M	4.52M	6.17M	0	0	0	86K	45K
Net Debt	3.52M	4.48M	5.23M	-15.68M	-16.54M	-4.1M	-7.94M	-4.22M
Debt / Equity	-	-	-	-	-	-	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-1.54x	-1.27x	-1.69x	-720.80x	-145.39x	-24.96x	-1048.07x
Total Equity+	-3.63M	-4.46M	-5.62M	16.62M	18.08M	11.02M	7.24M	1.82M
Equity Growth %	-	-0.23%	-0.26%	3.96%	0.09%	-0.39%	-0.34%	-0.75%
Book Value per Share	-62.94	-77.30	-144.96	340.57	442.28	248.10	132.73	4.02
Total Shareholders' Equity	-3.63M	-4.46M	-5.62M	16.62M	18.08M	11.02M	7.24M	1.82M
Common Stock	5K	5K	5K	78K	94K	94K	147K	0
Retained Earnings	-10.32M	-11.15M	-12.43M	-16.48M	-23.73M	-32.52M	-41.86M	-56.45M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-870K	-635K	-609K	-2.56M	-6.55M	-6.46M	-6.68M	-12.62M
Operating CF Margin %	-	-	-	-	-	-75.1%	-	-
Operating CF Growth %	-	0.27%	0.04%	-3.2%	-1.56%	0.01%	-0.03%	-0.89%
Net Income	-1.12M	-828K	-1.28M	-4.05M	-7.25M	-8.79M	-9.34M	-14.59M
Depreciation & Amortization	0	0	1K	987K	7K	15K	15K	16K
Stock-Based Compensation	18K	0	89K	38K	812K	1.39M	804K	310K
Deferred Taxes	0	0	2K	-987K	0	0	0	0
Other Non-Cash Items	257K	324K	613K	2.33M	412K	257K	218K	-16K
Working Capital Changes	-23K	-131K	-35K	-869K	-538K	672K	1.63M	1.66M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	-62K	-2K	720K	-585K	73K	12K	76K
Cash from Investing+	0	0	0	-10K	-50K	-6.01M	5.99M	-13K
Capital Expenditures	0	0	0	-10K	-50K	-6K	-9K	-13K
CapEx % of Revenue	-	-	-	-	-	0.07%	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-50K	-6K	0	0
Cash from Financing+	699K	488K	1.51M	17.31M	7.48M	0	4.62M	8.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	1.27M	0	1.48M	0	2.91M	3.51M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-870K	-635K	-609K	-2.57M	-6.6M	-6.46M	-6.69M	-12.63M
FCF Margin %	-	-	-	-	-	-75.17%	-	-
FCF Growth %	-	0.27%	0.04%	-3.22%	-1.57%	0.02%	-0.03%	-0.89%
FCF per Share	-15.09	-11.01	-15.70	-52.60	-161.51	-145.54	-122.63	-27.86
FCF Conversion (FCF/Net Income)	0.42x	0.77x	0.33x	0.63x	0.90x	0.73x	0.71x	0.87x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-73.7%	-41.76%	-60.42%	-102.34%	-321.92%
Return on Invested Capital (ROIC)	-	-1630.43%	-	-453.25%	-434.57%	-157.07%	-230.98%	-
Gross Margin	-	-	-	-	-	82.56%	-	-
Net Margin	-	-	-	-	-	-10223.26%	-	-
Debt / Equity	-	-	-	-	-	-	0.01x	0.02x
Interest Coverage	-	-1.54x	-1.27x	-1.69x	-720.80x	-145.39x	-24.96x	-1048.07x
FCF Conversion	0.42x	0.77x	0.33x	0.63x	0.90x	0.73x	0.71x	0.87x
Revenue Growth	-	-	-	-	-	-	-100%	-

Frequently Asked Questions

Growth & Financials

PainReform Ltd. (PRFX) grew revenue by 0.0% over the past year. Growth has been modest.

PainReform Ltd. (PRFX) reported a net loss of $4.1M for fiscal year 2024.

Dividend & Returns

PainReform Ltd. (PRFX) has a return on equity (ROE) of -321.9%. Negative ROE indicates the company is unprofitable.

PainReform Ltd. (PRFX) had negative free cash flow of $6.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener